Here's the problem: biology is generating data faster than anyone can analyze it.
Next-generation sequencing. Single-cell omics. Spatial transcriptomics. High-content imaging. The volume of biological data being produced has exploded — and traditional on-premises computing infrastructure simply can't keep up.
That's why cloud computing for cell biology, genomics and drug development has become one of the fastest-growing infrastructure markets in life sciences. Valued at $6.2 billion in 2024, it's projected to reach $15.6 billion by 2030 — a 16.7% CAGR.
The growth isn't just about storage. It's about computation. AI and machine learning workflows for drug target identification, molecular simulation and clinical trial optimization require elastic cloud resources and specialized GPU infrastructure that only hyperscale cloud platforms can deliver efficiently.
And it's democratizing access. Cloud-native bioinformatics SaaS platforms are enabling smaller biotechs and academic labs to run enterprise-grade analyses without building massive IT infrastructure. That's fundamentally changing who can compete in drug discovery.
North America leads with 44.7% market share, with key players spanning cloud hyperscalers (AWS, Google, Microsoft, IBM) and life sciences specialists (Benchling, DNAnexus, Rescale).
Want to understand where this market is headed? Download the free overview of our report Cloud Computing in Cell Biology, Genomics and Drug Development: Global Markets for complete segmentation, competitive landscape and technology analysis.
Download the Free Report Overview →